$MRNA
Moderna, Inc. Stock $mrna

$mrna Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000168285219000031 Filed on August 08, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$17.05M	$13.08M	$28.85M
YoY Change	-59.18%	-54.65%	-29.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$28.20M	$28.50M	$21.40M
YoY Change	52.43%	33.18%
% of Gross Profit
Research & Development	$119.6M	$128.3M	$104.5M
YoY Change	9.71%	22.8%
% of Gross Profit
Depreciation & Amortization	$7.300M	$7.500M	$5.900M
YoY Change	12.31%	27.12%	-37.89%
% of Gross Profit
Operating Expenses	$147.8M	$156.8M	$125.9M
YoY Change	15.86%	24.57%	-6.98%
Operating Profit	-$130.8M	-$143.7M	-$97.02M
YoY Change	52.37%	48.13%	2.99%
Interest Expense	$7.700M	$8.600M	$6.400M
YoY Change	22.22%	34.38%
% of Operating Profit
Other Income/Expense, Net	-$1.881M	-$1.877M	$171.0K
YoY Change	82.27%	-1197.66%
Pretax Income	-$123.4M	-$135.3M	-$90.44M
YoY Change	53.61%	49.56%
Income Tax	-$178.0K	-$324.0K	$158.0K
% Of Pretax Income
Net Earnings	-$123.2M	-$134.9M	-$90.60M
YoY Change	53.38%	48.94%
Net Earnings / Revenue	-722.84%	-1031.41%	-314.03%
Basic Earnings Per Share
Diluted Earnings Per Share	-$372.4K	-$409.8K	-$279.3K
COMMON SHARES
Basic Shares Outstanding	330.2M shares	329.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.059B	$1.070B	$1.115B
YoY Change	-1.26%	-4.0%
Cash & Equivalents	$173.7M	$151.6M	$140.6M
Short-Term Investments	$884.8M	$918.7M	$974.0M
Other Short-Term Assets	$11.00M	$9.000M	$29.00M
YoY Change	-60.71%	-68.97%
Inventory
Prepaid Expenses	$9.730M	$9.138M
Receivables	$2.800M	$3.498M	$12.00M
Other Receivables	$17.00M	$13.00M	$7.000M
Total Short-Term Assets	$1.094B	$1.097B	$1.163B
YoY Change	-2.11%	-5.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$203.7M	$208.5M	$202.0M
YoY Change	-1.12%	3.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$280.0M	$365.0M	$222.0M
YoY Change	86.67%	64.41%
Other Assets	$2.094M	$2.558M	$15.00M
YoY Change	-85.04%	-82.95%
Total Long-Term Assets	$496.4M	$587.9M	$439.0M
YoY Change	33.81%	33.91%
TOTAL ASSETS
Total Short-Term Assets	$1.094B	$1.097B	$1.163B
Total Long-Term Assets	$496.4M	$587.9M	$439.0M
Total Assets	$1.591B	$1.685B	$1.602B
YoY Change	6.84%	5.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.74M	$29.61M	$28.00M
YoY Change	-51.1%	5.75%
Accrued Expenses	$60.08M	$44.59M	$48.00M
YoY Change	33.51%	-7.11%
Deferred Revenue	$70.19M	$83.40M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$147.8M	$162.0M	$200.0M
YoY Change	-20.52%	-19.01%
LONG-TERM LIABILITIES
Long-Term Debt	$34.00M	$34.00M	$27.00M
YoY Change	25.93%	25.93%
Other Long-Term Liabilities	$161.0K	$188.0K	$226.0M
YoY Change	-99.92%	-99.92%
Total Long-Term Liabilities	$161.0K	$188.0K	$253.0M
YoY Change	-99.93%	-99.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$147.8M	$162.0M	$200.0M
Total Long-Term Liabilities	$161.0K	$188.0K	$253.0M
Total Liabilities	$339.1M	$346.7M	$453.0M
YoY Change	-17.9%	-23.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.370B	-$1.246B
YoY Change
Common Stock	$33.00K	$33.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.248B	$1.335B	-$688.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.591B	$1.685B	$1.602B
YoY Change	6.84%	5.2%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$123.2M	-$134.9M	-$90.60M
YoY Change	53.38%	48.94%
Depreciation, Depletion And Amortization	$7.300M	$7.500M	$5.900M
YoY Change	12.31%	27.12%	-37.89%
Cash From Operating Activities	-$107.0M	-$108.6M	-$48.20M
YoY Change	33.42%	125.31%	-74.07%
INVESTING ACTIVITIES
Capital Expenditures	-$6.700M	-$10.60M	-$34.10M
YoY Change	-74.33%	-68.91%	97.11%
Acquisitions
YoY Change
Other Investing Activities	$120.1M	-$236.3M	$22.40M
YoY Change	-15.6%	-1154.91%	-92.68%
Cash From Investing Activities	$113.4M	-$246.9M	-$11.60M
YoY Change	-2.24%	2028.45%	-104.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	15.80M	4.200M	110.4M
YoY Change	-266.32%	-96.2%	-7985.71%
NET CHANGE
Cash From Operating Activities	-107.0M	-108.6M	-48.20M
Cash From Investing Activities	113.4M	-246.9M	-11.60M
Cash From Financing Activities	15.80M	4.200M	110.4M
Net Change In Cash	22.20M	-351.3M	50.60M
YoY Change	-15.59%	-794.27%	-50.0%
FREE CASH FLOW
Cash From Operating Activities	-$107.0M	-$108.6M	-$48.20M
Capital Expenditures	-$6.700M	-$10.60M	-$34.10M
Free Cash Flow	-$100.3M	-$98.00M	-$14.10M
YoY Change	85.4%	595.04%	-91.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001682852
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	330182202	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Moderna, Inc.
CY2018Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	21578000	USD
	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue	8.69
CY2018Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	6.59
CY2019Q2	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	7.05
CY2019Q2	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	23186000	USD
CY2018Q4	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	22000000	USD
CY2019Q2	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	0	USD
CY2018Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	12089000	USD
CY2019Q2	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	5402000	USD
	mrna	Contract With Customer Asset Decrease During Period ContractWithCustomerAssetDecreaseDuringPeriod	5204000	USD
	mrna	Contract With Customer Asset Increase During Period ContractWithCustomerAssetIncreaseDuringPeriod	5110000	USD
	mrna	Contract With Customer Liability Decrease During Period ContractWithCustomerLiabilityDecreaseDuringPeriod	25165000	USD
	mrna	Contract With Customer Liability Increase During Period ContractWithCustomerLiabilityIncreaseDuringPeriod	2292000	USD
	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	2046000	USD
	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	1033000	USD
CY2018Q4	mrna	Lease Financing Obligation LeaseFinancingObligation	33489000	USD
CY2019Q2	mrna	Lease Financing Obligation LeaseFinancingObligation	33588000	USD
	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	13567000	USD
	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	0	USD
	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	13567000	USD
	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	6310000	USD
	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	2571000	USD
	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	-99000	USD
	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	1747000	USD
	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	3678000	USD
CY2019Q2	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	4.34
	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	3.89
CY2019Q2	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	9.68
CY2018Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	10089000	USD
CY2019Q2	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	6310000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31210000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	29609000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11686000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3498000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8948000	USD
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	899000	USD
CY2019Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1020000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	79073000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	44589000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	64456000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	79227000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1320000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2741000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2538155000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2582134000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14353000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26204000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	362960000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21495000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39992000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14353000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26204000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21495000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	365032000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39992000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	281259194	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	53147389	shares
CY2018Q4	us-gaap	Assets Assets	1962149000	USD
CY2019Q2	us-gaap	Assets Assets	1685279000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1563006000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	1097418000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1279865000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	1283754000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	916905000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	918722000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	863063000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	918722000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	172990000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	365032000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	28181000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6074000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140619000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	658364000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151624000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147608000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152982000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	670491000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163448000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5374000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-507043000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	328798904	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	329958172	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	328798904	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	329958172	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89460000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-163829000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-132904000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-263650000	USD
CY2018Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4612000	USD
CY2019Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4518000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	240924000	USD
CY2019Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	218051000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	109056000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	83401000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	81775000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	165352000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	139923000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.59
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23406000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16001000	USD
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	231700000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4M10D
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-14000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21387000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	161911000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	11583000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	25165000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	27984000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	82800000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	36500000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	400000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	100000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	25	security
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	11	security
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10006000	USD
CY2019Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	11039000	USD
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5900000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11031000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000000	USD
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14817000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37704000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28523000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55806000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-90443000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-162819000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-135378000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-268059000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	158000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	158000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-324000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-348000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1340000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1471000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-489000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8188000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-766000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	121000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-261000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-24959000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	70000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3987000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-27796000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2283000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-23100000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	792000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	53000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8872000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2315000	USD
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	7909000	USD
CY2019Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	7044000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6401000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11610000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	10322000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	21294000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	531000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2360000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	431908000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	346725000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1962149000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1685279000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	222803000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	161987000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	660357000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7764000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-495349000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-258660000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159634000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-256147000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-90601000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-162977000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-135054000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-267711000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-94082000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-169939000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-135054000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-267711000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	125866000	USD
	us-gaap	Operating Expenses OperatingExpenses	232307000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	157019000	USD
	us-gaap	Operating Expenses OperatingExpenses	314877000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-97015000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-174417000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-143936000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-285769000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	239171000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	20586000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	23697000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	24253000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	22481000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	137948000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	10206000	USD
CY2018Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4800000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	10000000	USD
CY2019Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	10200000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2644000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2558000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1141000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-852000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2150000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4061000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	597000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	591000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	17000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	14000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1738000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2167000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4075000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	608000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1148000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3464000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4388000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	188000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	171000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1764000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3584000	USD
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	474000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	837984000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	843313000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	65989000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18181000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28399000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22492000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10401000	USD
CY2019Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9138000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	661111000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	298376000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	563634000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	110248000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	39200000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4100000	USD
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	276433000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	287736000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	211977000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	208509000	USD
CY2019Q2	us-gaap	Property Subject To Or Available For Operating Lease Number Of Units PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits	2	campus
CY2018Q2	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	3481000	USD
	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	6962000	USD
CY2019Q2	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	104479000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	194603000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	128496000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	259071000	USD
CY2018Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	831000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	595000	USD
CY2019Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	62000	USD
CY2018Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11532000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11532000	USD
CY2019Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11762000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1006627000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1246354000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978643000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13083000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29108000	USD
CY2019Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	268200000	USD
CY2018Q2	us-gaap	Revenues Revenues	28851000	USD
	us-gaap	Revenues Revenues	57890000	USD
CY2019Q2	us-gaap	Revenues Revenues	13083000	USD
	us-gaap	Revenues Revenues	29108000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	26204000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	181371000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	50821132	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	39992000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	71300000.0	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	25559777	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14800000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4067618	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6280966	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.87
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	220434000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	51982687	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.16
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.14
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	20278000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	26422410	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	17.04
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.86
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.57
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.24
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	161093000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M15D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y11M
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1051793	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	152000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	70000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3930000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3987000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-551365000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-613709000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-688768000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1530241000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1446033000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	1338554000	USD
CY2018Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	509352795	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65938939	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65686290	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	329176107	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	328994058	shares

Files In Submission

Name	View Source	Status
0001682852-19-000031-index-headers.html	Edgar Link	pending
0001682852-19-000031-index.html	Edgar Link	pending
0001682852-19-000031.txt	Edgar Link	pending
0001682852-19-000031-xbrl.zip	Edgar Link	pending
a190425cellmapa03.jpg	Edgar Link	pending
a190805pipeline.jpg	Edgar Link	pending
exhibit101.htm	Edgar Link	pending
exhibit3116302019.htm	Edgar Link	pending
exhibit31206302019.htm	Edgar Link	pending
exhibit3216302019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
moderna10-q6302019.htm	Edgar Link	pending
modernalogo.jpg	Edgar Link	pending
mrna-20190630.xml	Edgar Link	completed
mrna-20190630.xsd	Edgar Link	pending
mrna-20190630_cal.xml	Edgar Link	unprocessable
mrna-20190630_def.xml	Edgar Link	unprocessable
mrna-20190630_lab.xml	Edgar Link	unprocessable
mrna-20190630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNA
Moderna, Inc. Stock $mrna

2019 Q3 Form 10-Q Financial Statement

#000168285219000031 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA Moderna, Inc. Stock $mrna

2019 Q3 Form 10-Q Financial Statement

#000168285219000031 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA
Moderna, Inc. Stock $mrna